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ESBLs are uncommon in Pseudomonas aeruginosa in the United Kingdom (UK), but may be 21 
frequent e.g. in parts of the Middle East [1]. The types of ESBL predominantly found in the 22 
species are unusual, with VEB and PER often encountered, rather than the CTX-M, SHV, and 23 
TEM variants that dominate in Enterobacteriaceae [1,2] 24 
From 2006-16, the Antimicrobial Resistance and Healthcare Associated Infections 25 
(AMRHAI) Reference Unit confirmed 30 VEB-positive P. aeruginosa isolates by PCR. Seven 26 
of these were from an outbreak in North West (NW) England, the early stages of which were 27 
described previously [2]; the remaining 23 were reference service submissions selected for 28 
blaVEB PCR tests based on either: (i) a ceftazidime MIC ≥256 mg/L reduced to ≤32 mg/L by 2 29 
mg/L clavulanate; or (ii) being from the same hospital as known positives and being resistant 30 
to ceftazidime at ≥256 mg/L, irrespective of ceftazidime/clavulanate potentia tion.  31 
   Despite their coming from 20 different hospitals we were struck that all 30 isolates 32 
had the VNTR profile 13, 2, 1, 5, 2, 3, 6, 5, x, determined as previously described [3], where 33 
‘x’ is variable. This profile corresponds to sequence type (ST) 357, a recognised ‘high-risk P. 34 
aeruginosa clone’ for metallo -lactamases (MBLs) [4]. These findings led us to screen 38 35 
further ST357 isolates – referred for typing but not susceptibility testing – identifying an 36 
additional 12 blaVEB positives and giving a final working collection of 42 VEB-positive ST357 37 
isolates from 36 patients at 26 hospitals (2006: one isolate, 2008: one isolate, 2010: four 38 
isolates, 2012: seven isolates, 2013: ten isolates, 2014: seven isolates, 2015: eleven isolates, 39 
2016: one isolate).  Although we receive incomplete information on patients’ origins and prior 40 
travels, many isolates were likely imports to the UK: among 15 isolates from 13 patients 41 
hospitalized in the London area 11 were from private hospitals with international clienteles, 42 
including many admissions from the Middle East.  Seven isolates originated from patients 43 
involved in a fire in Bucharest and transferred to different UK hospitals following prior 44 
hospitalisation in Romania.   45 
Fourteen isolates also had MBLs, as predicted from phenotypes and confirmed by 46 
PCR; 13 of these, including seven from the NW outbreak, had blaVIM; one had blaNDM. 47 
Irrespective of MBL co-production, the VEB-positive isolates were extremely resistant to 48 
antipseudomonal agents, as determined by BSAC agar dilution with EUCAST breakpoints 49 
(http://www.eucast.org).  Ceftazidime MICs all were ≥256 mg/L, carbenicillin ≥1024 mg/L, 50 
cefepime ≥64 mg/L and piperacillin/tazobactam ≥32mg/L, indicating consistent high -level 51 
resistance. All but one isolate were resistant to imipenem (41/42; 97.7%) whilst resistance to 52 
meropenem was observed in 40/42 (95.3%). Resistance to ciprofloxacin (MICs ≥4 mg/L) was 53 
universal and that to aminoglycosides was near universal (tobramycin MICs all ≥16 mg/L, 54 
100% non-susceptible; amikacin MICs 8-≥64 mg/L, 41/42 (97.7%) non-susceptible; 55 
gentamicin MICs 4-≥32 mg/L, 41/42 (97.7%) non-susceptible). All remained susceptible to 56 
colistin (MICs ≤2 mg/L). Where MBLs were absent (28/42 isolates), carbapenem resistance 57 
likely depended on loss of porin OprD, which is frequent in P. aeruginosa, although this was 58 
not examined directly. 59 
Despite their frequent ceftazidime/clavulanate synergy, all of the isolates were 60 
resistant to ceftolozane/ tazobactam, with MICs >16 mg/L, regardless of MBL co-production; 61 
it remains unclear whether this reflects poor penetration of P. aeruginosa by tazobactam or 62 
tazobactam having little capacity to inactivate VEB enzymes. The behaviour of 63 
ceftazidime/avibactam was more interesting. Avibactam evidently penetrates P. aeruginosa 64 
as it potentiates ceftazidime against AmpC-derepressed strains, and reportedly can inhibit 65 
extracted VEB -lactamases [5]. Nevertheless, and despite avibactam being used at double 66 
the concentration of clavulanate, resistance to ceftazidime/avibactam was observed in 95.3% 67 
of the isolates (40/42), with MICs above the 8+4 mg/L breakpoint and   mostly remained above 68 
those of ceftazidime/clavulanate (Table 1). 69 
From our experience, potentiation of ceftazidime by clavulanate coupled with 70 
resistance to ceftolozane/tazobactam (MIC >16 mg/L) have good specificity as indicators of 71 
VEB ESBLs in P. aeruginosa, but sensitivity is poor, with ceftazidime/clavulanate MICs for 72 
11.9% of producers identified here remaining above our top concentration of 32+2 mg/L.   73 
To date, the genome sequences of three ST357 P. aeruginosa isolates have been 74 
published, including one with a VEB-1 enzyme from a bloodstream infection in India. More 75 
generally, ST357 is well known as a ‘high-risk clone’ also for VIM and IMP MBLs [4].These 76 
carbapenemases, like VEB enzymes, are integron-borne, and ST357 may have a particular 77 
ability to host these elements, We did not examine blaVEB gene type or location in this study: 78 
previous characterization of isolates from the NW outbreak mostly found blaVEB-1, but with 79 
blaVEB-9 in one representative [2]. The blaVEB integron was chromosomally located in these 80 
outbreak isolates but has also been recorded on plasmids from P. aeruginosa in other studies.81 
  82 
Although VEB-positive P. aeruginosa remain uncommon in the UK, the present data 83 
show that they are repeatedly being introduced, commonly belong to an internationally 84 
successful lineage, and are extremely drug resistant - often remaining susceptible only to 85 
colistin.  At a time when international emphasis is on carbapenemase producers, they should 86 
not be underestimated.  87 
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Table 1. Relationship of ceftazidime/clavulanate and ceftazidime/avibactam MICs for P. 132 
aeruginosa with blaVEB 133 
Ceftazidime/clavulanate 
(MIC mg/L)* n 
Ceftazidime/avibactam 
(MIC mg/L) n MBL enzymes (n) 
4 1 2 1    
8 9 
16 4   
32 3   
>32 2   
16 14 
16 3 VIM (1) 
32 5   
>32 6 VIM (2) 
32 13 
8 1  
16 2 VIM (1) 
32 5 VIM (3) 
>32 5 VIM (3) 
>32 5 
32 1 VIM(1) 
>32 4 NDM(1), VIM (2) 
 134 
*MICs of unprotected ceftazidime were ≥256 mg/L in all cases 135 
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 140 
 141 
